Long-term Rituximab Therapy in Adult Patients with Idiopathic Nephrotic Syndrome.
Saudi J Kidney Dis Transpl
; 33(4): 509-515, 2022.
Article
em En
| MEDLINE
| ID: mdl-37929543
ABSTRACT
Patients with refractory idiopathic nephrotic syndrome (INS) are at risk of infections, renal failure, and the inherent side effects of immunosuppressive therapy. In the present study, we investigated the efficacy of yearly rituximab therapy in adult patients with this syndrome over 5-10 years. In the minimal change disease group, 14 of the 15 patients had complete remission (CR) and one had partial remission (PR). Of those who achieved CR, eight patients did not require rituximab 4 years later. The patient with PR was treated in the same way as those with focal segmental glomerulosclerosis (FSGS) group and remained stable by the end of the study. In the FSGS group, rituximab therapy resulted in the amelioration of INS in nine patients, although two were non-responders (NR) and developed end-stage renal disease (ESRD). In the membranous glomerulopathy group, 36 patients had CR but two were NR and developed ESRD. Twenty (55%) of those did not require treatment after 4 years, whereas the rest maintained CR with yearly rituximab. Nine women received rituximab after the third month of pregnancy without significant adverse effects on the fetus or subsequent conception. In conclusion, rituximab is a safe, practical, and effective long-term therapy for adult patients in these three groups of INS.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Glomerulosclerose Segmentar e Focal
/
Falência Renal Crônica
/
Nefrose Lipoide
/
Síndrome Nefrótica
Limite:
Adult
/
Female
/
Humans
Idioma:
En
Revista:
Saudi J Kidney Dis Transpl
Ano de publicação:
2022
Tipo de documento:
Article